NCT06851858 - Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

July 8, 2026

Study Completion Date

July 8, 2026

Conditions

EndocrinologyDiabetes, Type IIObesity

Interventions

DRUG

AZD6234

Weekly SC injections of AZD6234

DRUG

Placebo to match

Weekly SC injections of matching placebo

Trial Locations (18)

30114

RECRUITING

Research Site, Canton

31210

WITHDRAWN

Research Site, Macon

32216

RECRUITING

Research Site, Jacksonville

32789

RECRUITING

Research Site, Winter Park

33135

RECRUITING

Research Site, Miami

33136

RECRUITING

Research Site, Miami

33166

RECRUITING

Research Site, Doral

35205

RECRUITING

Research Site, Birmingham

36608

RECRUITING

Research Site, Mobile

37909

RECRUITING

Research Site, Knoxville

40509

RECRUITING

Research Site, Lexington

60523

RECRUITING

Research Site, Oak Brook

60640

RECRUITING

Research Site, Chicago

64114

RECRUITING

Research Site, Kansas City

67114

RECRUITING

Research Site, Newton

73069

RECRUITING

Research Site, Norman

78229

RECRUITING

Research Site, San Antonio

89119

RECRUITING

Research Site, Las Vegas